Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,269 SEK | +7,60% | -1,10% | -0,74% |
Vakgebied
Aantal werknemers: 21
Verkoop per activiteit
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Stem Cell Therapies
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Verkoop per regio
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Sweden
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 67 | 01-01-09 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 01-01-13 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 01-03-17 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 01-01-21 |
Chairman | 67 | 01-01-11 | |
Director/Board Member | 64 | 01-01-22 | |
Director/Board Member | 61 | 01-01-21 | |
Director/Board Member | 62 | 01-01-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 567 006 473 | 175 183 114 ( 30,90 %) | 0 | 30,90 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. |
Biotechnology
|
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,74% | 14,48 mln. | |
+43,36% | 54,63 mld. | |
-5,31% | 39,92 mld. | |
+14,75% | 26,86 mld. | |
-12,56% | 26,22 mld. | |
-22,45% | 18,78 mld. | |
+25,12% | 12,21 mld. | |
+0,04% | 12,16 mld. | |
+26,04% | 11,94 mld. | |
-11,83% | 10,74 mld. |
- Beurs
- Aandelen
- Koers XINT
- Onderneming Xintela AB